Novartis Pharmaceuticals has made available Fanapt (iloperidone) tablets, an atypical antipsychotic, for the acute treatment of schizophrenia in adults. Fanapt, a mixed dopamine D2/serotonin 5HT2A receptor antagonist, was first approved by the FDA on May 6, 2009.

For more information call (888) 669-6682 or visit www.fanapt.com.